PubMed ID:
11565517
Public Release Type:
Journal
Publication Year: 2001
Affiliation: Department of Medicine, Rush-Presbyterian-St Luke's Medical Center, Chicago, IL 60612, USA.
DOI:
https://doi.org/10.1056/NEJMoa011303
Authors:
Lewis JB,
Atkins RC,
Berl T,
Clarke WR,
Collaborative Study Group,
Hunsicker LG,
Lewis EJ,
Pohl MA,
Raz I,
Ritz E,
Rohde R
Studies:
Chronic Renal Insufficiency Cohort Study
It is unknown whether either the angiotensin-II-receptor blocker irbesartan or the calcium-channel blocker amlodipine slows the progression of nephropathy in patients with type 2 diabetes independently of its capacity to lower the systemic blood pressure.